ArticleDrug design, development and therapy2026
Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: CDK4/6 (Cyclin-dependent kinase 4/6) inhibitors are recommended as the first-line treatment for Hormone receptor-positive/human epidermal growth receptor 2-negative (HR+/HER2-) breast cancer, but their efficacy is limited. Metformin, a widely used antidiabetic drug, has demonstrated antitumor potential and can enhance the efficacy of various cancer therapies. Nevertheless, its specific role in sensitizing HR+/HER2- breast cancer to CDK4/6 inhibition and the underlying mechanisms remain poorly defined. Methods: In this study, the combined anti-HR+/HER2- breast cancer effects of metformin with CDK4/6 inhibitor palbociclib and its potential mechanisms were investigated using human HR+/HER2- breast cancer cell lines in vitro and transplanted tumor mouse models in vivo. Results: Our study demonstrated that the combination of metformin and palbociclib synergistically inhibited proliferation and migration, and promoted apoptosis in HR+/HER2- breast cancer cells. This synergistic anticancer effect was linked to suppression of the PI3K/AKT/mTOR pathway. Mechanistically, metformin downregulated CDK4 protein expression, and its combination with palbociclib led to a more profound suppression of Cyclin D1 and E2F, along with enhanced inhibition of Rb phosphorylation. Moreover, the metformin-palbociclib combination synergistically suppressed tumor growth in vivo. Conclusion: Our findings highlighted that metformin could serve as an adjunctive therapy alongside CDK4/6 inhibitors, offering a promising synergistic treatment strategy for HR+/HER2- breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.